Kanamycin-OVA
Kanamycin-OVA is a conjugate of Kanamycin and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells[1].
Product Specifications
UNSPSC
12352100
Target
Biochemical Assay Reagents
Related Pathways
Others
Field of Research
Inflammation/Immunology
Smiles
[Kanamycin-OVA]
References & Citations
[1]YANAGISAWA K, et al. Studies on kanamycin, a new antibiotic against tubercle bacilli. I. Effect on virulent tubercle bacilli in vitro and in mice. J Antibiot (Tokyo) . 1957 Nov;10 (6) :233-5.
Shipping Conditions
Room temperature
Scientific Category
Biochemical Assay Reagents
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040679-500 1x 500 µL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040525-500 1x 500 µL
CD63 (MX-49.129.5), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC941283-500 1x 500 µL
VEGI (Vascular Endothelial Growth Inhibitor) (VEGI/1283), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details